Strategic Initiatives Coupled With Increasing Investments in R&D Activities to Drive the Global Cancer Gene Therapy Market

Published: May 2022

The global cancer gene therapy market is anticipated to grow at a considerable CAGR of 23.1% during the forecast period. One of the key factors that are fueling the market is the growing competitiveness between the market players. With several key players in the market, companies are advancing, innovating, and launching new products to stay in the competition. For instance, in April 2022, Labcorp enhances cell and gene therapy development support through collaboration with X-cell biosciences. Labcorp and Xcellbio plan to collaborate on several projects aimed at increasing the safety and efficacy of cell and gene therapies (CGTs). This demonstrates Labcorp's commitment to expanding its global, comprehensive suite of CGT capabilities, while also assisting pharmaceutical and biotechnology businesses in their attempts to accelerate medicinal development.

Browse the full report description “Global Cancer Gene Therapy Market Size, Share & Trends Analysis Report by Therapy (Gene Transfer Immunotherapy, Oncolytic Virotherapy, and Gene Induced Immunotherapy), and by End-Users (Hospitals, Research Institutes, and Biotech Companies) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/cancer-gene-therapy-market 

Furthermore, in February 2022, BioMarin Pharmaceutical Inc. reported updates on its investigational gene therapy programs in clinical development. The company received additional requests from the Food and Drug Administration (FDA) for information required to resolve the clinical hold of the PHEARLESS Phase 1/2 study of BMN 307, which was issued in September 2021.

Another major factor contributing to the growth of the market is the increase in the adoption of various strategic initiatives such as mergers and acquisitions, partnerships, and others to stay competitive in the market. For instance, in December 2021, Novartis acquired Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness. This has increased better options available for end-users and increased the demand for various cancer gene therapies.

Market Coverage

  • The market number available for – 2021-2028
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Therapy
  • By End-Users

Regions Covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- including Amgen, Inc., Biogen Inc., Bluebird Bio, Gilead Sciences, INC., Novartis, and others.

 Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How has COVID-19 impacted the market?

oDeviation from the pre-COVID-19 forecast

oMost affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Cancer Gene Therapy Market Report Segment

By Therapy

  • Gene Transfer Immunotherapy 
  • Oncolytic Virotherapy 
  • Gene Induced Immunotherapy 

oDelivery of Cytokines Gene 

oDelivery of Tumor Antigen Gene 

By End-Users

  • Hospitals 
  • Research Institutes
  • Biopharma Companies 

Global Cancer Gene Therapy Market Report Segment by Region

North America

  • US
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
    • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/cancer-gene-therapy-market